Related Experiment Video

Updated: Oct 24, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Potential benefit of biventricular pacing in patients with congestive heart failure and ventricular tachyarrhythmia

C Stellbrink1, A Auricchio, B Diem

  • 1Department of Cardiology and Internal Medicine, University of Technology, Aachen, Germany.

The American Journal of Cardiology
|March 25, 1999
PubMed

Insights

Biventricular pacing may improve outcomes for congestive heart failure (CHF) patients, especially those with advanced disease. This therapy, combined with defibrillation, could benefit a significant portion of CHF patients at risk for ventricular arrhythmias.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Heart Failure Management

Background:

  • Congestive heart failure (CHF) treatment focuses on symptom relief and mortality reduction.
  • Implantable cardioverter defibrillators (ICDs) prevent sudden cardiac death but lack proven mortality benefits in advanced CHF.
  • Biventricular pacing shows potential for functional improvement in select CHF patients.

Purpose of the Study:

  • To evaluate the potential benefit of biventricular pacing in patients with congestive heart failure (CHF).
  • To identify the proportion of CHF patients meeting eligibility criteria for biventricular pacing based on NYHA class and QRS duration.

Main Methods:

  • Retrospective analysis of 384 CHF patients' data.
  • Assessment of New York Heart Association (NYHA) CHF class, QRS duration, PR interval, and atrial fibrillation incidence.
  • Application of biventricular pacing eligibility criteria to patient data.

Main Results:

  • Advanced CHF patients (NYHA class III) were older with longer mean QRS duration and PR intervals.
  • Higher incidence of atrial fibrillation observed in NYHA class III patients.
  • 7.3% of patients met criteria for biventricular pacing (NYHA class III), and 12.5% (NYHA class II with ejection fraction ≤30%).

Conclusions:

  • Biventricular pacing, combined with defibrillation, is a potential therapeutic strategy for advanced CHF.
  • A significant proportion of CHF patients may benefit from biventricular pacing, particularly those at risk for ventricular tachyarrhythmia.

More Related Videos

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...